Nature Medicine conducted two CRISPR related articles on Monday. Both studies found that the CRISPR-Cas9 system can induce intracellular p53-mediated DNA damage and affect CRISPR genome editing. CRISPR-related companies’ share prices dropped sharply after the article went live, CRISPR Therapeutics fell nearly 13%, Editas Medicine fell nearly 8%, Intellia Therapeutics… Continue Reading Nature issued a document, the stock price dropped! How does p53 affect the future of CRISPR?
Clinically, it is often encountered that many women suffer from low blood pressure in their youth. It seems that middle-aged people have become hypertensive for a year or two. Individual women find it difficult to accept this. Why does this happen? This is mainly related to changes in female hormones.… Continue Reading Why does the blood pressure of females rise rapidly after middle age?
At present, about 2 billion people in the world are obese, and obesity is also a high risk factor for causing diseases. Amazingly, obesity and intestinal flora are also closely related. In the SELF Forum Women’s Workshop, Zhang Chenhong, an associate researcher at the School of Life Science and Technology… Continue Reading 5 months lost 100 pounds! The effective method is to regulate the intestinal flora
The appearance of PD-1/L1 inhibitors about five or six years ago has triggered a frantic fever in the field of cancer treatment. This class of drugs can use the immune system to fight cancer by relieving the tumor’s suppression of the human immune system. For a small percentage of patients,… Continue Reading The path to tumor immunocombination therapy
Many studies have shown that the intestinal microflora can significantly affect the therapeutic effects of some anti-cancer drugs. However, how should it be developed into therapeutic methods and applied to the clinic to improve the efficacy of anti-cancer drugs? Bertrand Routy’s reputation in Parisian oncologist circles was not very good… Continue Reading Can intestinal flora help cancer research?
CAR-T therapy has attracted wide attention due to its bright prospects in the treatment of cancers such as leukemia and lymphoma. This new type of therapy, which has just entered the market, usually requires the injection of hundreds of millions of genetically engineered T cells into patients. However, in a… Continue Reading Only one cell is used to cure a cancer patient!
Sage Therapeutics announced on May 30 that the FDA has accepted a new drug marketing application (NDA) for brexanolone (SAGE-547) intravenous injection to treat postpartum depression and granted priority review status. The PDUFA is scheduled to expire on December 19, 2018. Brexanolone is an allosteric modulator of the gamma-aminobutyric acid… Continue Reading The First Postpartum Depression New Drug Applicant Listed, Obtained FDA Priority Review Qualification
Alzheimer’s disease may have originated from some unknown type of diabetes! This rather shocking hypothesis is expected to open up new avenues for the treatment of Alzheimer’s disease and even to find preventive measures. “Alzheimer’s disease is diabetes in the brain.” This remark first aroused great repercussions in the field… Continue Reading Is Alzheimer’s disease called “Type III” diabetes?
Hemophilia is a hereditary blood coagulation dysfunction hemorrhagic disease with the disease gene located on the X chromosome, excluding about a third of spontaneous mutations or genetic changes. Men are mainly affected, and women are mostly “carriers.” Common features of hemophilia are active thrombinogenic disorders, prolonged clotting time, and a… Continue Reading Progress in Clinical Drugs for Hemophilia
In a large LEADER study involving 9340 patients with type 2 diabetes with higher cardiovascular risk, liraglutide reduced the risk of cardiovascular death, non-fatal MI, and non-fatal stroke by 13%. The risk of death was reduced by 15% and the risk of cardiovascular death was reduced by 22%. At the… Continue Reading Liraglutide: Got natural hypoglycemic, part-time weight loss, but dislike for no effect on heart failure?